RE: Another arrow to our bow22 Jan 2024 09:17
I thought it was "another string to your bow"? LOL!
Totally agree. Angle are simply pointing out to the World that their Parsortix system is the best one to use.
"The review article details research from multiple independent, leading cancer centres, such as The University of Athens, Greece, University Medical Center Hamburg-Eppendorf, Germany, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy, the Health Research Institute of Santiago (IDIS), Spain and Edith Cowan University, Australia. The benefits of utilising the Parsortix system for downstream molecular analysis is showcased across these cancer centres in various cancer types including non-small cell lung cancer, triple negative breast cancer, head and neck cancer, colorectal cancer, and melanoma, highlighting the wide utility of the Parsortix system.
In support of ANGLE's breakthrough data, DNA variants were identified in some studies that were exclusive to CTCs, as compared to ctDNA, and the combined molecular analysis of CTCs and ctDNA in a research setting increased the number of patients identified with a potentially actionable biomarker, providing a more comprehensive gene variant profile. This enhanced gene variant profile has the potential, subject to further study, to inform on prognosis, treatment selection, monitoring of treatment resistance and disease relapse.
The Parsortix system is identified as the *****optimal technology for this purpose***** as, with Parsortix label-free microfluidic isolation, all phenotypes of CTCs can be harvested intact and undamaged providing easily accessible samples for molecular analysis with low white blood cell background.".
All IMHO.
Sign In
Follow the stocks
